Hemo Organic

how big is Hemo Organic?

As of Jun 06, Hemo Organic Ltd has a market capitalization of 4.00 Cr, with recent net sales of 2.41 Cr and a net profit of 0.16 Cr. The latest balance sheet shows shareholder's funds of -0.32 Cr and total assets of 0.92 Cr.

Market Cap: As of Jun 06, Hemo Organic Ltd has a market capitalization of 4.00 Cr, classifying it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest 4 quarters, Hemo Organic reported Net Sales of 2.41 Cr and a Net Profit of 0.16 Cr. This data is based on Standalone financials.<BR><BR>Balance Sheet Snapshot: The Standalone balance sheet for the latest annual period ending in Mar'24 shows Shareholder's Funds of -0.32 Cr and Total Assets of 0.92 Cr.

Who are in the management team of Hemo Organic?

As of March 2021, the management team of Hemo Organic includes Dineshbhai S Patel (Chairman & Managing Director), Sonal D Patel (Executive Director), Krushanakant R Patel (Independent Director), Sanjeev Lodha (Additional Independent Director), Siyona Jhnawar (Director), and Nishita Mayank Sanghvi (Company Secretary).

As of March 2021, the management team of Hemo Organic includes the following members:<BR><BR>1. Dineshbhai S Patel - Chairman & Managing Director<BR>2. Sonal D Patel - Executive Director<BR>3. Krushanakant R Patel - Independent Director<BR>4. Sanjeev Lodha - Additional Independent Director<BR>5. Siyona Jhnawar - Director<BR>6. Nishita Mayank Sanghvi - Company Secretary<BR><BR>These individuals play key roles in the governance and management of the company.

What does Hemo Organic do?

Hemo Organic Ltd produces and sells white coal, ayurvedic medicines, and chemicals, classified as a Micro Cap company. As of March 2025, it reported net sales of 2 Cr and a market cap of Rs 4 Cr.

Overview:<BR>Hemo Organic Ltd is engaged in the production and sale of white coal, ayurvedic medicines, and chemicals within the Trading & Distributors industry, classified as a Micro Cap company.<BR><BR>History:<BR>Incorporated in August 1992, Hemo Organic Ltd was formerly known as Dinesh Allorga Limited. The company initially focused on manufacturing chemicals but discontinued this due to a pollution crisis. The latest quarterly results reported net sales and profit for March 2025.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 2 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 4 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 4.00 <BR>Industry P/E: 32 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.47 <BR>Return on Equity: -16.00% <BR>Price to Book: -3.73 <BR><BR>Contact Details:<BR>Address: 8-A Gulnar Chinar-Gulnar Apart, V V Nagar Road Anand Gujarat : 388001 <BR>Tel: 91-2692-248535 <BR>Email: drdineshpatel@rediffmail.com <BR>Website: http://www.hemoorganic.com

Has Hemo Organic declared dividend?

No Dividend History Available

Who are the peers of the Hemo Organic?

Hemo Organic's peers include Redington, MMTC, MSTC, Ravindra Energy, Saptak Chem &, and Chambal Brewer. Redington shows excellent management and growth, while Ravindra Energy has the highest 1-year return at 141.63%, and Hemo Organic's return is -4.95%.

Peers: The peers of Hemo Organic are Redington, MMTC, MSTC, Ravindra Energy, Saptak Chem &, and Chambal Brewer.<BR><BR>Quality Snapshot: Excellent management risk is observed at Redington, while Average management risk is found at MMTC and MSTC, and the rest have Below Average or do not qualify. Growth is Excellent at Redington, Below Average at MMTC and MSTC, while Ravindra Energy has Below Average growth, and Saptak Chem & does not qualify. In terms of Capital Structure, Excellent is noted at MSTC, Good at Redington, and the rest have Below Average or do not qualify.<BR><BR>Return Snapshot: Ravindra Energy has the highest 1-year return at 141.63%, while MSTC has the lowest at -39.89%. Hemo Organic's 1-year return is -4.95%, which is higher than MSTC's but lower than Ravindra Energy's. Additionally, MSTC and Chambal Brewer have negative six-month returns.

Is Hemo Organic overvalued or undervalued?

As of April 1, 2024, Hemo Organic's valuation has shifted to risky due to overvaluation indicated by a PE ratio of 3.75 and poor performance compared to peers, with its stock declining 83.96% over the past three years versus a 49.13% increase in the Sensex.

As of 1 April 2024, Hemo Organic's valuation grade has moved from does not qualify to risky, indicating a shift in perception regarding its financial health. The company appears to be overvalued based on its current metrics, with a PE ratio of 3.75, an EV to EBIT of -5.22, and a PEG ratio of 0.02, all of which suggest significant financial distress and poor profitability.<BR><BR>In comparison to its peers, Hemo Organic's valuation stands out negatively against companies like Altius Telecom, which has a PE ratio of 52.97 and is rated very attractive, and Sagility India, which is rated fair with a PE of 33.73. The stark contrast in these ratios highlights Hemo Organic's struggles within the trading and distribution industry. Additionally, the company's stock performance has lagged behind the Sensex, particularly over the past three years, where it has declined by 83.96% compared to a 49.13% increase in the index.

What is the technical trend for Hemo Organic?

As of June 2, 2025, Hemo Organic's trend is sideways with mixed signals: while the weekly and monthly MACD and Bollinger Bands show mild bullishness, daily moving averages indicate short-term weakness, resulting in overall market indecision.

As of 2 June 2025, the technical trend for Hemo Organic has changed from mildly bullish to sideways. The weekly MACD remains mildly bullish, while the monthly MACD is also mildly bullish, indicating some positive momentum. However, the daily moving averages are mildly bearish, suggesting short-term weakness. The Bollinger Bands are bullish on both weekly and monthly time frames, which supports the overall bullish sentiment. The KST shows a mixed picture with weekly mildly bullish and monthly mildly bearish readings. Both the Dow Theory and RSI indicate no clear trend. Overall, the current stance is neutral with mixed signals, reflecting indecision in the market.

Who are the top shareholders of the Hemo Organic?

The top shareholders of Hemo Organic include Dineshbhai Shanabhai Patel with 15.49%, and the Indian Clearing Corporation Limited at 8.08%. Individual investors collectively own 71.11% of the shares, with no institutional holdings or pledged promoter shares reported.

The top shareholders of Hemo Organic include Dineshbhai Shanabhai Patel, who holds the largest stake at 15.49%. The highest public shareholder is the Indian Clearing Corporation Limited, with an ownership of 8.08%. Additionally, individual investors collectively hold a significant portion of the company, accounting for 71.11% of the shares. There are no institutional holdings or pledged promoter shares reported.

How has been the historical performance of Hemo Organic?

Hemo Organic has shown significant financial improvement from March 2024 to March 2025, with net sales rising from 0.02 Cr to 2.41 Cr and a turnaround in profitability, achieving a profit after tax of 0.16 Cr. However, the company faces challenges with increased total liabilities, which rose to 4.70 Cr.

Answer:<BR>The historical performance of Hemo Organic shows significant fluctuations in financial metrics over the years, particularly from March 2019 to March 2025.<BR><BR>Breakdown:<BR>Hemo Organic's net sales have seen a notable increase from Mar'24 at 0.02 Cr to Mar'25 at 2.41 Cr, marking a substantial growth. However, the total expenditure also rose sharply to 2.46 Cr in Mar'25 from 0.27 Cr in Mar'24, leading to an operating profit (PBDIT) of 0.02 Cr in Mar'25, a recovery from a loss of 0.25 Cr in the previous year. The profit before tax improved to 0.03 Cr in Mar'25, compared to a loss of 0.26 Cr in Mar'24, and the profit after tax turned positive at 0.16 Cr, reversing from a loss of 0.26 Cr. Despite these improvements, the company's total liabilities increased to 4.70 Cr in Mar'25 from 0.92 Cr in Mar'24, while total assets also rose to 4.70 Cr. The book value per share adjusted to -0.44 in Mar'25, an improvement from -0.91 in Mar'24. The earnings per share (EPS) showed a positive shift to 0.46 in Mar'25 from -0.75 in Mar'24, indicating a recovery in profitability. Overall, while Hemo Organic has made strides in revenue and profit metrics, it continues to face challenges with its liabilities and book value.

When is the next results date for Hemo Organic Ltd?

The next results date for Hemo Organic Ltd is 13 February 2026.

The next results date for Hemo Organic Ltd is scheduled for 13 February 2026.

Are Hemo Organic Ltd latest results good or bad?

Hemo Organic Ltd's latest Q2 FY26 results are concerning, showing a net loss of -₹0.03 crores and zero revenue, indicating significant operational challenges. With a negative book value per share and increased liabilities, the company's financial health appears poor.

Hemo Organic Ltd's latest results for Q2 FY26 are quite concerning. The company reported a net profit of -₹0.03 crores, indicating a loss for the quarter, and recorded zero revenue, which is consistent with the previous quarter. This lack of sales raises significant doubts about the company's operational viability.<BR><BR>Additionally, the book value per share is negative at -₹0.44, suggesting that the company has more liabilities than assets, which is a serious red flag for investors. The overall financial performance indicates a troubling trend, with only one profitable quarter in the last seven, making it difficult to view the company's future positively.<BR><BR>The balance sheet shows a negative net worth and a dramatic increase in trade payables, further highlighting liquidity issues. Given these factors, the latest results can be classified as bad, reflecting a company in distress with significant operational and financial challenges.

Should I buy, sell or hold Hemo Organic Ltd?

Which are the latest news on Hemo Organic?

Why is Hemo Organic Ltd falling/rising?

As of 31-Mar, Hemo Organic Ltd's stock price is falling to 11.70, down 4.96%. The stock has significantly underperformed, with declines in both short-term and long-term metrics, compounded by reduced investor interest and fundamental financial weaknesses.

As of 31-Mar, Hemo Organic Ltd's stock price is falling, currently at 11.70, reflecting a change of -0.61, or -4.96%. The stock has been underperforming significantly, with a decline of -8.67% over the past week and -27.06% over the past month, compared to a lesser decline of -1.03% and -10.33% in the Sensex, respectively. <BR><BR>The stock has also been on a consecutive downward trend for the last three days. It is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a persistent weakness in its price performance. Additionally, there has been a notable drop in investor participation, with delivery volume on March 27 falling by 98.4% against the 5-day average, suggesting reduced interest from investors.<BR><BR>The overall sector performance has also contributed to the stock's decline, with the Miscellaneous sector falling by -3.22%. Furthermore, the company faces significant challenges, including a negative book value and a weak long-term fundamental strength, characterized by poor growth in net sales and operating profit over the last five years. The stock's risk profile is heightened due to negative EBITDA and a high debt-to-equity ratio, further discouraging investment.<BR><BR>In summary, the combination of poor recent performance, declining investor interest, and underlying financial weaknesses are driving Hemo Organic Ltd's stock price down.